Utah is currently home to 1224 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Salt Lake City, Murray, Ogden and West Jordan. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
A First-in-Human, Phase 1/2 Study of LAT010 in Patients with Advanced Solid Tumors (LIGHTSPEED-1)
NCT06277219
Recruiting
This is an open-label, multicenter, Phase 1/2, first-in-human (FIH), dose-escalation and cohort-expansion study of LAT010 to evaluate the safety, tolerability, immunogenicity, PK, PD, and antitumor activity in patients with advanced solid tumors. The study consists of 2 parts: Phase 1 dose-escalation and Phase 2 cohort expansion.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/11/2024
Locations: Huntsman Cancer Institute, Salt Lake City, Utah
Conditions: Advanced Solid Tumor
Register for Updates
A Study to Learn About the Study Medicine (Nirmatrelvir Plus Ritonavir) in Pregnant Women With COVID-19
NCT05386472
Recruiting
The purpose of this clinical trial is to learn about how study medicine (Paxlovid, which contains nirmatrelvir and ritonavir) is changed and eliminated from the body, as well as its safety, and the extent to which side effects can be tolerated for treatment of pregnant women with mild or moderate COVID-19 compared to non-pregnant women with mild or moderate COVID-19. This study is seeking participants who: * are expecting a healthy baby and are in their second or third trimester pregnancy and... Read More
Gender:
FEMALE
Ages:
Between 18 years and 50 years
Trial Updated:
10/11/2024
Locations: University of Utah, Salt Lake City, Utah
Conditions: COVID-19
Register for Updates
Evaluating Intuitive 3D Models in Preoperative Surgical Planning for Thoracic and Colorectal Procedures.
NCT06434727
Recruiting
The Study Objective: To evaluate the clinical utility of a 3D model with 2D CT/MRI scans during simulated preoperative surgical planning of open, laparoscopic, or robotic-assisted anatomic lung resection (segmentectomy, lobectomy) or Lower Anterior Resection (LAR) procedures.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/10/2024
Locations: University of Utah, Salt Lake City, Utah
Conditions: Thoracic, Colorectal Disorders
Register for Updates
Study of Talazoparib in Combination With Chemotherapy in Relapsed Pediatric AML to Determine Safety and Efficacy
NCT05101551
Recruiting
This is a Phase 1, open label, multicenter, dose finding study with dose expansion intended to evaluate the safety and tolerability of talazoparib in combination with conventional chemotherapy. Preliminary estimates of efficacy will be obtain through a dose expansion cohort receiving the maximum tolerated dose from the dose escalation phase of the study. This study aims to determine the safety of talazoparib in combination with conventional chemotherapy and to establish the maximum tolerated do... Read More
Gender:
ALL
Ages:
21 years and below
Trial Updated:
10/10/2024
Locations: University of Utah, Salt Lake City, Utah
Conditions: Acute Myeloid Leukemia
Register for Updates
Study of Pelvic Hypofractionated Radiotherapy in Endometrial Cancer
NCT04683653
Recruiting
This study will investigate if a shorter treatment course (known as "hypofractionation") for pelvic radiation is safe for women with endometrial cancer. Doctors leading the study will also determine the safest and most tolerable dose of shortened radiation (hypofractionation) used to treat women in this study. Because this study will shorten the radiation course typically used to treat endometrial cancer, each daily treatment given to women in this study will be slightly higher than normal to en... Read More
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
10/09/2024
Locations: Huntsman Cancer Institute, Salt Lake City, Utah
Conditions: Endometrial Cancer
Register for Updates
Mono vs. Dual Therapy for Pediatric Pulmonary Arterial Hypertension
NCT04039464
Recruiting
The investigators' central hypothesis is that early combination therapy with two PAH-specific oral therapies that have been shown to be well tolerated in the pediatric population, sildenafil and bosentan, will result in better World Health Organization (WHO) functional class at 12 months after initiation of PAH treatment than therapy with sildenafil alone.
Gender:
ALL
Ages:
Between 3 months and 18 years
Trial Updated:
10/09/2024
Locations: University of Utah Hospital, Salt Lake City, Utah
Conditions: Pediatric Pulmonary Hypertension
Register for Updates
A Study of a N, N-dimethyltryptamine (DMT) Analog (CYB004) in Participants with Generalized Anxiety Disorder (GAD)
NCT06051721
Recruiting
The purpose of this proof-of-concept trial is to examine the safety, tolerability, and pharmacokinetics (PK), and preliminary clinical efficacy of CYB004 participants with GAD.
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
10/08/2024
Locations: Cedar Clinical Research, Murray, Utah
Conditions: Generalized Anxiety Disorder
Register for Updates
PCMS Task After Moderate-to-severe Stroke
NCT05736653
Recruiting
Researchers at the University of Pittsburgh are conducting a research study to see how combining brain, nerve, and hand stimulation affect hand movement after stroke. The primary purpose of this study is to examine changes in the connection between the brain and the weak hand muscles after the combined brain, nerve, and hand stimulation. The primary hypothesis is that the combined brain, nerve, and hand stimulation will increase the the connection between the brain and the weak hand muscles. The... Read More
Gender:
ALL
Ages:
Between 18 years and 80 years
Trial Updated:
10/08/2024
Locations: Neural Plasticity Rehabilitation and Movement Dynamics Lab, Salt Lake City, Utah
Conditions: Stroke
Register for Updates
The Neonatal Hemorrhagic Risk Assessment in Thrombocytopenia
NCT04598750
Recruiting
This is a prospective observational study designed to evaluate Immature Platelet Fraction or Immature Platelet Count and Platelet Function Analyzer-100/200 Closure Time-ADP (in vitro bleeding time) as markers of bleeding risk in thrombocytopenic preterm neonates admitted to the Neonatal Intensive Care Unit.
Gender:
ALL
Ages:
1 day and above
Trial Updated:
10/07/2024
Locations: Intermountain Medical Center, Murray, Utah
Conditions: Neonatal Thrombocytopenia, Bleeding
Register for Updates
A Study About How TAK-881 is Processed by the Body and Side Effects in People With Primary Immunodeficiency Diseases
NCT05755035
Recruiting
The main aim of this study is to evaluate the PK, safety, tolerability and immunogenicity of subcutaneous (SC) administration of TAK-881 in adult and pediatric participants with PIDD and compare them to HYQVIA in participants 16 years old and older. The participants will be treated with TAK-881/HYQVIA or HYQVIA/TAK-881 with the same dose and dosing interval of immunoglobulin for up to 51 weeks (for participants greater than or equal to \[\>=\]16 years) and only with TAK-881 for up to 27 weeks (... Read More
Gender:
ALL
Ages:
2 years and above
Trial Updated:
10/04/2024
Locations: Tanner Clinic, Murray, Utah
Conditions: Primary Immunodeficiency Diseases (PID)
Register for Updates
Combination Therapies With Adagrasib in Patients With Advanced NSCLC With KRAS G12C Mutation
NCT05609578
Recruiting
Study CA239-0010 is an open-label, Phase 2 clinical trial evaluating the clinical efficacy of adagrasib in combination with pembrolizumab and chemotherapy in the first-line setting for patients with advanced NSCLC with TPS ≥ 1%, TPS \<50% and KRAS G12C mutation
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/04/2024
Locations: Local Institution - Unk010, Salt Lake City, Utah
Conditions: Advanced NSCLC, Metastatic Lung Cancer
Register for Updates
Postmarketing Prospective Study of Melanoma Patients Treated With IMLYGIC® to Characterize Risk of Herpetic Infection
NCT02910557
Recruiting
A postmarketing Cohort study of Melanoma patients treated with IMLYGIC (Talimogene Laherparepvec) in clinical Practice to Characterize the risk of herpetic infection with detection of Talimogene Laherparepvec DNA among patients, close contacts, and health care providers; and long term safety in treated patients for up to 5 years after the first IMLYGIC dose.
Gender:
ALL
Ages:
All
Trial Updated:
10/04/2024
Locations: Intermountain Medical Center, Murray, Utah
Conditions: Melanoma, Herpetic Infection
Register for Updates